1 / 12

Lopinavir/Ritonavir- A Promising Co-Formulated Drug

Lopinavir/ritonavir combination is the first and only coformulated HIV-1 protease inhibitor. Clinical trials have demonstrated lopinavir/ritonaviru2019s immunologic and virologic benefits of treatment of HIV-infected adults, adolescents, and children. Recently, studies revealed that a combination of Lopinaviru2013Ritonavir were proven effective against SARS-CoV and MERS-CoV, the previous two coronaviruses that hit the globe.

JazzCrystal
Télécharger la présentation

Lopinavir/Ritonavir- A Promising Co-Formulated Drug

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lopinavir/Ritonavir- A Promising Co-Formulated Drug

  2. End of December 2019 and beginning of the year 2020 marked the emergence of, a novel coronavirus, designated SARS-CoV-2, and has caused an international outbreak of respiratory illness termed Covid-19. The full spectrum of Covid-19 ranges from mild, self-limiting respiratory tract illness to severe progressive pneumonia, multi-organ failure, and finally death.

  3. Although there is no therapeutic treatment for coronavirus agents till date but in a hopeful finding, studies revealed that a combination of Lopinavir–Ritonavir were proven effective against SARS-CoV and MERS-CoV, the previous two coronaviruses that hit the globe.

  4. Originally, Lopinavir/ritonavir combination is the first and only coformulated HIV-1 protease inhibitor. Clinical trials have demonstrated lopinavir/ritonavir’s immunologic and virologic benefits of treatment of HIV-infected adults, adolescents, and children.

  5. Recently a random, controlled, open-label trial for lopinavir–ritonavir (ritonavir helps to stabilize lopinavir) in 199 hospitalized patients with severe COVID-19 was conducted and the drug showed benefit for some secondary endpoints.Pharmaceutical parlance, medicinal fraternity and researchers are trying ways to find a promising treatment for the deadly virus. A lot of research is going on throughout the world and a lot of hard work, knowledge, infrastructure, technology and research material is required to find a cure for COVID -19.

  6. Some of the possible known and unknown impurities of Lopinavir required in clinical trials are tabulated below:

  7. Pharmaffiliates provides all the above-mentioned products for research and quality control purpose. In the critical time of pandemic, Pharmaffiliates assures to deliver on time and in a cost effective manner.We deliver all the research products with a Certificate of Analysis along with necessary data required to fulfill your regulatory needs.

More Related